Related references
Note: Only part of the references are listed.Specific glycosaminoglycan chain length and sulfation patterns are required for cell uptake of tau versus alpha-synuclein and beta-amyloid aggregates
Barbara E. Stopschinski et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2018)
Binding and neurotoxicity mitigation of toxic tau oligomers by synthetic heparin like oligosaccharides
Peng Wang et al.
CHEMICAL COMMUNICATIONS (2018)
Tau Internalization is Regulated by 6-O Sulfation on Heparan Sulfate Proteoglycans (HSPGs)
Jennifer N. Rauch et al.
SCIENTIFIC REPORTS (2018)
Heparan Sulfate as a Therapeutic Target in Tauopathies: Insights From Zebrafish
Seyedeh Maryam Alavi Naini et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2018)
The prion model for progression and diversity of neurodegenerative diseases
Barbara E. Stopschinski et al.
LANCET NEUROLOGY (2017)
Targeting heparin and heparan sulfate protein interactions
Ryan J. Weiss et al.
ORGANIC & BIOMOLECULAR CHEMISTRY (2017)
Tau Oligomers: Cytotoxicity, Propagation, and Mitochondrial Damage
Scott S. Shafiei et al.
FRONTIERS IN AGING NEUROSCIENCE (2017)
Characterization of tau prion seeding activity and strains from formaldehyde-fixed tissue
Sarah K. Kaufman et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2017)
Glycan Determinants of Heparin-Tau Interaction
Jing Zhao et al.
BIOPHYSICAL JOURNAL (2017)
A century of heparin: past, present and future
H. C. Hemker
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2016)
Prions and Protein Assemblies that Convey Biological Information in Health and Disease
David W. Sanders et al.
NEURON (2016)
Tau Prion Strains Dictate Patterns of Cell Pathology, Progression Rate, and Regional Vulnerability In Vivo
Sarah K. Kaufman et al.
NEURON (2016)
Heparinase I-specific disaccharide unit of heparin is a key structure but insufficient for exerting anti-prion activity in prion-infected cells
Kenta Teruya et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2015)
Tau Trimers Are the Minimal Propagation Unit Spontaneously Internalized to Seed Intracellular Aggregation
Hilda Mirbaha et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Sensitive Detection of Proteopathic Seeding Activity with FRET Flow Cytometry
Jennifer L. Furman et al.
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS (2015)
Demystifying Heparan Sulfate-Protein Interactions
Ding Xu et al.
ANNUAL REVIEW OF BIOCHEMISTRY, VOL 83 (2014)
Proteopathic tau seeding predicts tauopathy in vivo
Brandon B. Holmes et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Pathophysiology of heparan sulphate: many diseases, few drugs
U. Lindahl et al.
JOURNAL OF INTERNAL MEDICINE (2013)
Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds
Brandon B. Holmes et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Enoxaparin treatment administered at both early and late stages of amyloid β deposition improves cognition of APPswe/PS1dE9 mice with differential effects on brain Aβ levels
Nienke M. Timmer et al.
NEUROBIOLOGY OF DISEASE (2010)
Propagation of Tau Misfolding from the Outside to the Inside of a Cell
Bess Frost et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Continuous intraventricular infusion of pentosan polysulfate: Clinical trial against prion diseases
Yoshio Tsuboi et al.
NEUROPATHOLOGY (2009)
Neuroprotective properties of glycosaminoglycans: Potential treatment for neurodegenerative disorders
B. Dudas et al.
NEURODEGENERATIVE DISEASES (2008)
Long term survival in a patient with variant Creutzfeldt-Jakob disease treated with intraventricular pentosan polysulphate
A. Parry et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2007)
Experimental treatments for human transmissible spongiform encephalopathies: is there a role for pentosan polysulfate?
N. G. Rainov et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2007)
Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model
Yasumasa Yoshiyama et al.
NEURON (2007)
Structural impact of heparin binding to full-length Tau as studied by NMR spectroscopy
Nathalie Sibille et al.
BIOCHEMISTRY (2006)
Cerebroventricular infusion of pentosan polysulphate in human variant Creutzfeldt-Jakob disease
NV Todd et al.
JOURNAL OF INFECTION (2005)
Heparan sulfate is a cellular receptor for purified infectious prions
L Horonchik et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Treatment of transmissible spongiform encephalopathy by intraventricular drug infusion in animal models
K Doh-Ura et al.
JOURNAL OF VIROLOGY (2004)
Peripheral treatment with enoxaparin, a low molecular weight heparin, reduces plaques and β-amyloid accumulation in a mouse model of Alzheimer's disease
L Bergamaschini et al.
JOURNAL OF NEUROSCIENCE (2004)
Novel heparan mimetics potently inhibit the scrapie prion protein and its endocytosis
O Schonberger et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2003)
Cellular heparan sulfate participates in the metabolism of prions
O Ben-Zaken et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
1976-1983, a critical period in the history of heparin: the discovery of the antithrombin binding site
M Petitou et al.
BIOCHIMIE (2003)
Low molecular weight glycosaminoglycan blockade of β-amyloid induced neuropathology
M Walzer et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2002)
The blood-brain barrier accessibility of a heparin-derived oligosaccharides C3
Q Ma et al.
THROMBOSIS RESEARCH (2002)
Oral and subcutaneous administration of the glycosaminoglycan C3 attenuates A beta(25-35)-induced abnormal tau protein immunoreactivity in rat brain
B Dudas et al.
NEUROBIOLOGY OF AGING (2002)
Heparin and low-molecular-weight heparin - Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety
J Hirsh et al.
CHEST (2001)
An update on heparins at the beginning of the new millennium
J Fareed et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2000)
Share Paper
